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Abstract: Radix Angelica Sinensis (RAS) and Rhizome Ligusticum (RLC) combination is 
a popular herb pair commonly used in clinics for treatment of blood deficiency syndrome 
in China. The aim of this study is to compare the pharmacokinetic properties of ferulic acid 
(FA),  a  main  bioactive  constituent  in  both  RAS  and  RLC,  between  normal  and  blood 
deficiency syndrome animals, and to investigate the influence of compatibility of RAS and 
RLC on the pharmacokinetic of FA. The blood deficiency rats were induced by injecting 
2% Acetyl phenylhydrazine (APH) on the first day, every other day, to a total of five times, 
at the dosage of 100, 50, 50, 30, 30 mg/kg body mass, respectively. Quantification of FA in 
rat plasma was achieved by using a simple and rapid HPLC method. Plasma samples were 
collected at different time points to construct pharmacokinetic profiles by plotting drug 
concentration versus time, and estimate pharmacokinetic parameters. Between normal and 
blood deficiency model groups, both AUC(0–t) and Cmax of FA in blood deficiency rats after 
RAS-RLC extract administration increased significantly (P < 0.05), while clearance (CL) 
decreased significantly. Among three blood deficiency model groups, t1/2α, Vd, AUC(0–t) and 
AUC(0–∞) all increased significantly in the RAS-RLC extract group compared with the RAS 
group. The results indicated that FA was absorbed better and eliminated slower in blood 
deficiency rats; RLC could significantly prolong the half-life of distribution, increase the 
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volume of distribution and the absorption amount of FA of RAS in blood deficiency rats, 
which may be due to the synergic action when RAS and RLC were used together to treat 
blood deficiency syndrome. 
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1. Introduction 
Angelica sinensis (Oliv.) Diels (Umbelliferae) is a well known medicinal plant and also a famous 
traditional Chinese herb widely distributed in western China. The radix of Angelica sinensis (RAS), called 
Danggui, was first recorded in ―Shen Nong Ben Cao Jing‖ in the Han Dynasty (200–300 A.D.) [1].  
It has been used as one of the most important traditional Chinese medicines in Asia to enrich blood  
and  invigorate  blood  circulation  [2].  Danggui  has  been  regarded  as  ―female’s  ginseng‖  as  it  was 
extensively  applied  to  the  treatment  of  gynecological  disorders,  such  as  menstrual  disorders, 
amenorrhea, dysmenorrhea, and premenstrual syndrome [3–5]. Chuanxiong, the rhizome of Ligusticum 
chuanxiong Hort (RLC) (Umbelliferae), another well known traditional Chinese herb, has been widely 
used to treat cardiovascular disorders such as stroke, hypertension, and arrhythmia [6]. Moreover, RLC 
has been prescribed for ―dispersal of tissue stasis, removal of chronic inflammation and facilitation of 
tissue perfusion‖ [6]. From data mining in a Chinese medicine formula database, the simultaneous 
usage of two herbs (RAS and RLC) appears over 1200 times [7] and thus it is considered as a herb pair 
which is a basic unit in formulae, as well as an important bridge between single herb and formulae 
according to Traditional Chinese Medicine (TCM) theory. When two single herbs were applied as herb 
pair they may produce a synergistic, an additive, or an antagonistic effect. Interestingly, these two 
herbs can be used together as unique formulae named Fo-Shou-San (FSS), which contains RAS and 
RLC in a weight ratio of 3:2. FSS was prescribed for the treatment of women’s ailments, especially 
obstetric diseases, including dystocia, vaginal bleeding with fetal movement, dead fetus in uterus, and 
postpartum  anemic  fainting  [8,9].  On  the  basis  of  the  herb  pair,  many  classical  formulae  were 
composed under the guidance of TCM theory, such as Si-Wu-Tang (RAS, RLC, Radix Rehmanniae, 
and Radix Paeonia in a ratio of 1:1:1:1) [10,11] and its serial formulae [12,13]. 
RAS and RLC are both famous Chinese herbs from the Umbelliferae plants. They contain many 
aromatic acids and phthalides as major bioactive constituents. The aromatic acids, including among 
others ferulic acid, chlorogenic acid, caffeic acid, protocatechuic acid, vanillic acid, have antioxidant, 
antimicrobial,  anti-inflammatory,  and  anti-thrombosis  activities  [14–16].  The  phthalides,  including 
ligustilide,  butylidenephthalide,  senkyunolide  I,  senkyunolide  H,  have  antifungal,  antibacterial,  
anti-inflammatory  and  antioxidant  activities,  as  well  as  smooth  muscle  relaxant,  and  vasodilation 
activities [4,10,17]. Ferulic acid (FA), a characteristic aromatic acid in both RAS and RLC [18], is 
usually used as one of the forming compounds to assess quality [19] and has been clinically used to 
treat angina pectoris and hypertensive diseases in China [20]. Previous investigations suggested that it 
could significantly improve blood fluidity, inhibit platelet aggregation, decrease serum lipids, prevent 
thrombus formation, protect neuron like PC12 cells, and exhibit strong antioxidant activity [17,18,21–24]. 
FA  was  also  reported  to  have  anti-inflammatory  action  [25],  can  prevent  ethanol-induced  liver  Int. J. Mol. Sci. 2012, 13  3585 
 
 
injury [26], contribute to the defense against viral infections including AIDS [27], as well as suppress 
the  production  of  interleukin-8  (IL-8)  which  was  the  main  cause  of  the  local  accumulation  of 
neutrophils, and modulate various inflammatory reactions [25]. Since FA has been demonstrated to 
exhibit so many pharmacological effects, the understanding of pharmacokinetics of FA is useful for 
designing and dosing regimens in pharmacological studies. Furthermore, the pharmacokinetic profile 
can contribute to the safety and efficacy of FA in clinical applications. 
The pharmacokinetics of FA per se and/or in the TCM extracts [28] and combined formulae [29,30] 
have been studied in several works, and all performed in normal animals. However, little work has 
been carried out to investigate pharmacokinetics of FA in pathological state. It is well known that the 
pharmacokinetic process of a drug may be altered when the body is in morbidity, even significantly 
different from that in normal conditions. Therefore, it is necessary to study the potential alterations  
of  pharmacokinetic  parameters  under  pathological  conditions.  Furthermore,  the  data  obtained  
from  pathological  conditions  could  be  more  beneficial  than  those  from  normal  conditions  in  
clinical applications. 
RAS and RLC, especially the herb pair RAS-RLC, were clinically used for treatment of women’s 
ailments resulting from blood deficiency in TCM. In the herbs, FA was found to exhibit significant 
effects on syndrome of blood deficiency [31]. Therefore, in this study, the pharmacokinetic profile of 
FA was investigated and compared in normal and blood deficiency rat plasma after oral administration 
of RAS, RLC, and RAS-RLC. Moreover, the related pharmacokinetic profiles of FA are evaluated to 
analyze the different pharmacokinetic processes in normal and pathological conditions, and to discuss 
the variation after RAS and RLC were combined into herb pair. 
2. Results 
2.1. General and Hemogram Observation of Rats 
Normal rats are strong, vigorous, with brilliant pink eyes, clean pink moist nose and lips, round 
pink tail, straight back and loin, their fur is luxuriant and lustrous. Three days after APH administration, 
the animals appeared exhausted, sluggish, body curled into a ball with raised hairs, asthmatic and 
somnolent, tail, face, ears and eyes pale and cool. The signs of blood deficiency rats matched the same 
description of blood deficiency symptoms. 
Additionally, the periphery blood indexes in normal and blood deficiency rats are shown in Table 1, 
including white blood cell (WBC), red blood cell (RBC), hemoglobin (HGB), and hematocrit (HCT) 
which were the main diagnostic criteria of blood deficiency syndrome. Results showed that RBC, 
HGB,  and  HCT  in  blood  deficiency  rats  reduced  significantly  (P  <  0.05),  while  WBC  increased 
significantly (P < 0.05) in comparison with normal rats, indicating that the blood deficiency model was 
successfully induced [32]. Int. J. Mol. Sci. 2012, 13  3586 
 
 
Table 1. The periphery blood index in normal and blood deficiency rats ( x  ±  s). 
Group  WBC/10
9· L
1  RBC/10
12· L
1  HGB/g· L
1  HCT/% 
Normal  14.78 ±  3.31  7.01 ±  1.59  140.87 ±  10.22  0.42 ±  0.04 
Model  133.25 ±  10.04 **  3.72 ±  0.88 **  92.33 ±  5.28 **  0.33 ±  0.05 ** 
Compared  with  normal  group:  **  P  <  0.01.  White  blood  cell  (WBC),  red  blood  cell  (RBC), 
hemoglobin (HGB), and hematocrit (HCT). 
2.2. HPLC Chromatograms 
Under the conditions described above, the typical HPLC chromatograms of blank plasma, blank 
plasma spiked with FA and IS (IS: cinnamic acid; the chemical structures of FA and IS were given in 
Figure 1), and plasma samples, obtained 15 min after administration of RAS-RLC extract, from normal 
and  blood  deficiency  rats  are  presented  in  Figure  2.  The  retention  times  of  FA  and  IS  were 
approximately 6.7 and 10.4 min, respectively. No significant endogenous peaks were observed within 
the time frame in which FA and IS were detected. 
Figure 1. Chemical structures of: (A) ferulic acid (FA); and (B) cinnamic acid (IS). 
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Figure  2.  Representative  chromatograms  of  blank  plasma  sample  (A),  blank  plasma 
sample spiked with FA at 1.095 μg/mL and IS (B), plasma sample of normal rats at 15 min 
after oral administration of Radix Angelica Sinensis (RAS)-Rhizome Ligusticum (RLC) 
extract (C) and plasma sample of blood deficiency rats at 15 min after oral administration 
of RAS-RLC extract (D). 
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2.3. Validation of Chromatographic Methods 
The  peak  area  ratio  of  FA  to  IS  vs.  the  FA  concentration  curve  was  linear  over  the  range  of 
0.1095~10.95  μg/mL,  and  the  detection  limit  was  0.10  μg/mL.  With  the  least-squares  method,  a 
regression equation of C (μg/mL) = 8.5265AFA/AIS − 0.5074 (r = 0.999 7), where AFA/AIS was the peak 
area ratio of ferulic acid to cinnamic acid, and C was the ferulic acid concentration in μg/mL was 
obtained. The coefficients of variation (RSD) values of intra-day assay were 1.22, 3.67 and 4.85% at 
high, medium, and low concentrations of FA, respectively (n = 5). The coefficients of variation (RSD) 
values of inter-day assay were 2.85, 4.00 and 8.77% at high, medium, and low concentrations of FA, 
respectively (n = 5). The accuracy of FA was within the range of 81.12~98.98%. The recovery rates of 
FA from rat plasma were 88.03 ±  2.98%, 85.54 ±  1.75% and 82.25 ±  2.03% at high, medium, and low 
concentrations of FA, respectively. The coefficients of variation (RSD) of recovery rates were less than 
10%. The results of precision and recovery rates were conformed to the principle of bio-sample analysis. 
2.4. Determination of FA in Plasma and Pharmacokinetic Analysis 
The validated method was successfully applied to the pharmacokinetic study of FA in rat plasma 
after oral administration of RAS, RLC, and RAS-RLC extract. The mean concentration-time curves 
are shown in Figure 3, and the pharmacokinetic parameters are shown in Table 2. Int. J. Mol. Sci. 2012, 13  3588 
 
 
Figure 3. Plasma concentration-time curves of FA in normal (N) and blood deficiency rats 
(M) after oral administration of RAS, RLC and RAS-RLC extract (at a dose of 6.48, 7.19, 
7.35 mg/kg FA). Each point and bar represents the mean ±  S.D. (n = 6). 
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Table 2. Pharmacokinetic parameters of FA in normal and blood deficiency rats plasma 
after oral administration of RAS, RLC and RAS-RLC extract (at a dose of 6.48, 7.19,  
7.35 mg/kg FA). 
Parameters 
Normal    Blood deficiency 
RAS  RLC  RAS-RLC    RAS  RLC  RAS-RLC 
t1/2α (min)  3.902 ±  0.783  28.728 ±  5.813 
Δ  28.797 ±  5.208    5.342 ±  0.802  31.231 ±  3.493  28.984 ±  3.066 
# 
t1/2β (min)  45.785 ±  6.224  53.125 ±  7.663  37.126 ±  2.545    21.787 ±  2.693  23.121 ±  4.005  30.117 ±  2.056 
Vd (L/mg)  7.965 ±  1.002  50.882 ±  8.135 
ΔΔ  23.005 ±  3.031    4.318 ±  0.228  9.633 ±  2.209  14.972 ±  0.206 
# 
CL (L/min/kg)  0.886 ±  0.237  0.905 ±  0.218  0.760 ±  0.186    0.732 ±  0.056  0.327 ±  0.093  0.114 ±  0.002 * 
AUC(0–t) (mg/L· min)  21.649 ±  5.292  16.925 ±  3.368  20.194 ±  5.000    38.504 ±  4.912  88.685 ±  5.589  118.336 ±  5.876 * 
## 
AUC(0–∞) (mg/L· min)  25.689 ±  2.664  29.013 ±  2.276  27.412 ±  3.638    51.487 ±  4.240  94.457 ±  5.898  175.970 ±  3.437 
## 
K10 (1/min)  0.759 ±  0.018  0.018 ±  0.004 
Δ  0.035 ±  0.015    0.309 ±  0.043  0.077 ±  0.000  0.008 ±  0.000 
K12 (1/min)  0.615 ±  0.187  0.002 ±  0.000 
ΔΔ  0.043 ±  0.003    0.318 ±  0.059  0.030 ±  0.000  0.013 ±  0.001 
K21 (1/min)  0.040 ±  0.015  0.022 ±  0.001  0.013 ±  0.003    0.070 ±  0.024  0.012 ±  0.000  0.014 ±  0.001 
Tmax (min)  9.898 ±  1.025  5.000 ±  0.000  8.775 ±  1.202    9.996 ±  0.889  16.667 ±  2.583  15.000 ±  0.010 
Cmax (mg/L)  0.444 ±  0.112  0.321 ±  0.026  0.582 ±  0.124    0.918 ±  0.320  1.962 ±  0.042  1.088 ±  0.202 * 
Blood deficiency groups compared with their normal groups, respectively (* P < 0.05); Compared 
with normal group (RAS) (
Δ P < 0.05, 
ΔΔ P < 0.01); Compared with blood deficiency group (RAS) 
(
# P < 0.05, 
## P < 0.01). 
3. Discussion 
Acetyl phenylhydrazine is a strong oxidant, which has a slowly progressive and oxidative damage 
effect on RBC, especially interfering with glucose-6-phosphate dehydrogenase in RBC, promoting the 
changes  from  hemoglobin  to  Heinz-body,  and  making  the  RBC  disintegrate  easily,  which  finally 
results in hemolytic anemia of the body. The number of RBC then decreases and the content of HGB Int. J. Mol. Sci. 2012, 13  3589 
 
 
reduces significantly. As the number of WBC and rRBC pathologically increase, the liver and spleen 
swells and their color changes to dark red. All the results conform to the essential features of blood 
deficiency syndrome. It has been a standard procedure to induce rat blood deficiency and it is recorded 
in several textbooks [33,34] and literatures [35,36]. According to the procedures recorded in these 
reports  and  with  slight  modification,  we  have  successfully  reproduced  an  APH  induced  blood 
deficiency model. In order to decrease bleeding, we supplemented physiological saline (1 mL) once 
every hour by intraperitoneal injection during the period of blood collection. All the experiments of 
control groups and model groups were operated in a similar manner. 
Diagnosis and treatment based on an overall analysis of the illness and the patient’s condition is the 
essence of TCM theory. Rational drug therapy is dependent upon a basic understanding of the way 
patients handle drugs (pharmacokinetics) and their response to specific drug effects (pharmacodynamics). 
Many researches have demonstrated that disease condition will cause the alterations of pharmacokinetic 
parameters  [37–39].  Moreover,  traditional  Chinese  syndrome  state  and  the  drugs  combination  in 
traditional  Chinese  recipe  could  significantly  influence  the  blood  drug  concentration  and  their 
pharmacokinetic parameters after oral administration [40,41]. Until now, there are no pharmacokinetic 
data concerning FA in TCM extract or of combined formulae in the pathological condition of blood 
deficiency,  which  would  assist  in  providing  dosing  information  and  thus  enhance  the  safety  and 
efficacy of TCM utilizing  FA in  clinical applications. Moreover, since TCMs are administered in 
abnormal conditions in clinical practice, these related results obtained from normal conditions would 
not prove the clinical efficacy of TCM containing FA. 
In the present study, the pharmacokinetic profiles of FA were evaluated and compared after oral 
administration  of  RAS,  RLC,  and  RAS-RLC  extract.  Results  showed  that  the  pharmacokinetic 
parameters of FA after oral administration of RAS-RLC extract were significantly different between 
normal and blood deficiency rats. The plasma drug concentration-time data of FA in normal and blood 
deficiency rats were best fitted to a two-compartment open model, coinciding with the results of other 
researchers [42]. After oral administration of RAS, RLC, and RAS-RLC extracts in model rats of 
blood deficiency and their respective control rats, the absorption of FA was rapid; FA was detected in 
plasma from the first blood sampling time (2 min) and the plasma concentration reached its peak (Cmax) 
at  5  min  (tmax)  for  all  groups  of  rats  (Figure  3),  which  was  similar  to  the  results  found  in  the  
literature  [42–44].  After  reaching  a  Cmax,  the  plasma  concentrations  of  FA  declined  in  a 
polyexponential  fashion  for  each  group  of  rats  except  the  RLC  M  group,  in  which  the  plasma 
concentration of FA at 30 min was higher than that at 15 min, while lower than that at 5 min. which 
was the phenomenon of two-peaks in pharmacokinetic, mainly caused by the intestinal reabsorption of 
enterohepatic cycling. At the same time point, the plasma concentrations of FA in model rats were 
higher than their respective control rats. It was reported that, the pharmacokinetic profile of FA was 
significantly different after administration of pure FA and RLC decoction with the same dose and 
administration method. Tmax of pure FA and FA in RLC decoction was 10 and 2 min, respectively [43]. 
The  results  in  Table  2  showed  that  after  administration  of  RAS  or  RLC  single  herb,  the 
pharmacokinetic parameters of FA in blood deficiency rats had no significant differences compared 
with their respective normal rats. But AUC(0–t) and Cmax of FA increased significantly (P < 0.05) in 
blood  deficiency  rats  administrated  with  RAS-RLC  extract  compared  with  normal  rats,  while  CL 
decreased significantly (P < 0.05). After oral administration of RAS-RLC extract, the AUC(0-t) and Int. J. Mol. Sci. 2012, 13  3590 
 
 
Cmax values of FA increased significantly in blood deficiency rats, which is probably due to an increase 
in absorption of FA from the gastrointestinal tract of the rat models of blood deficiency. As reported, 
the liver and spleen of blood deficiency rats induced by acetyl phenylhydrazine are swollen and dark 
red compared with  normal  rats  due to the tissues  being closely  correlated  with  the hematological 
system [9]. The rats with blood deficiency syndrome reveal abnormal hemorheology with sluggish 
blood circulation, leading to the change of hemorrheology parameters including the increase of whole 
blood  viscosity,  plasma  viscosity,  hematocrit  and  ﬁbrinogen  [36,45].  FA  is  mainly  absorbed  in 
stomach and small intestine; poor blood circulation will prolong retention time in the stomach and 
small intestine and cause the increase of FA’s absorption. Liver is one of the main metabolic organs, 
therefore,it  is  impossible  for  FA  to  be  metabolized  quickly  because  of  the  pathological  change  
(e.g.,  some  metabolic  enzymes)  in  the  liver.  This  phenomenon  may  well  be  attributable  to  the 
biological  changes  of  some  enzymes  and  the  biomembrane  transfer  abilities  under  pathological 
conditions  [39,41].  These  results  demonstrated  that  there  was  significant  influence  on  the 
pharmacokinetics of FA when RAS and RLC were used in combination as a herb pair, which may be 
due to the synergic action between RAS and RLC. All the results indicated that FA was absorbed 
better and eliminated slower in blood deficiency rats. 
Furthermore,  the  results  in  Table  2  show  that,  among  the  three  normal  groups,  there  were  no 
significant differences between RAS and RAS-RLC groups, RLC and RAS-RLC groups; nor was there 
any significant difference after dose correction. Pharmacokinetic parameters of t1/2α and Vd in RLC 
group  were  increased  significantly  compared  with  RAS  group,  while  K10  and  K12  decreased 
significantly,  but  the  main  pharmacokinetic  parameters  of  AUC  and  Cmax  showed  no  significant 
differences. It merely indicated that FA of RLC in normal rats had wider distribution and lower rate 
constants of transport between the central and peripheral compartments compared with RAS, which 
might be attributed to the difference in components between RAS and RLC. Among the three blood 
deficiency  groups,  however,  there  were  significant  differences  only  between  RAS  and  RAS-RLC 
groups, and there were significant differences after dose correction, too. Pharmacokinetic parameters 
of  t1/2α,  Vd,  AUC(0–t)  and  AUC(0–∞)  increased  significantly  (P  <  0.05)  in  RAS-RLC  extract  group 
compared with RAS group. It also revealed that RLC could significantly raise some pharmacokinetic 
parameters of RAS such as t1/2α, Vd, AUC(0–t) and AUC(0–∞) when RAS and RLC used together in blood 
deficiency rats. In other words, RLC could significantly prolong the half-life of distribution, increase 
the  volume  of  distribution  and  the  absorption  of  FA  of  RAS  in  blood  deficiency  rats.  This  was 
probably caused by newly produced components when RAS  and RLC were used  in combination, 
indicating the synergic action between RAS and RLC. However, there were no significant differences 
between RLC and RAS-RLC groups, indicating that RLC could prolong the half-life and increase the 
apparent volume of distribution and absorption of FA in blood deficiency rats. These results suggested 
that RAS could have a better effect on nourishing and tonifying blood efficacy with the assistance of 
RLC,  and  reflecting  the  scientific  essence  of  mutual  promotion  and  assistance  of  RAS-RLC  as  a  
herb pair. 
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4. Experimental Section 
4.1. Materials and Extraction 
The radix of Angelica sinensis (Oliv.) Diels (Umbelliferae) was collected at Min County, Gansu 
Province,  China,  in  June  2009.  The  rhizome  of  Ligusticum  chuanxiong  Hort  (Umbelliferae)  was 
collected  at  Pengzhou  Sichuan,  China,  also  in  June  2009.  They  were  identified  by  Dr.  Hui  Yan 
(Department  of  Pharmacognosy,  Nanjing  University  of  Chinese  Medicine,  Nanjing,  China).  The 
voucher specimen (No. NJUTCM-20080701) was deposited in the Herbarium of Nanjing University of 
Chinese Medicine. 
The dry herb materials of RAS (2 kg) and RLC (2 kg) were crushed to pieces, extracted with 
boiling water (1:8) for twice, 2 h for each time, filtered through gauze. The residue was refluxed with 
95% ethanol once under the same conditions. Then three filtrates were merged and evaporated by 
rotary  evaporation  under  vacuum  at  60  ° C,  thus  RAS  and  RLC  extract  samples  were  obtained, 
respectively. The concentration of FA was 0.46 mg/g in the extract of RAS and 0.51 mg/g of RLC.  
A total 2 kg mixed pieces of RAS-RLC (1:1, w/w) were extracted through the same procedure. The 
concentration of FA in the extract of RAS-RLC was 0.52 mg/g. 
4.2. Animals 
Male  and  female  Sprague-Dawley  (SD)  rats  (180–220  g)  were  obtained  from  Shanghai  Slac 
Laboratory Animal Co. Ltd. (Shanghai), and kept in an environmentally controlled breeding room 
(temperature: 20 ±  2 ° C, humidity: 60 ±  5%) for 1 week before the experiments started. The rats were 
fasted for 12 h with free access to water prior to the experiments. Animal welfare and experimental 
procedures were strictly in accordance with the Guide for the Care and Use of Laboratory Animals 
(US National Research Council, 1996) and the related ethics regulations of Nanjing University of 
Chinese Medicine. 
4.3. Chemicals and Reagents 
The  reference  standard  of  FA  (98%)  and  internal  standard  (IS),  cinnamic  acid  (98%),  were 
purchased  from  the  National  Institute  for  the  Control  of  Pharmaceutical  and  Biological  Products 
(Beijing,  China).  N-Acetyl  phenylhydrazine  (APH)  was  purchased  from  Tianjin  Institute  of  Fine 
Chemicals  retrocession  (Tianjin,  China).  Acetonitrile  of  HPLC  grade  was  obtained  from  Tedia 
(Fairfield, OH, USA). Ethyl acetate, hydrochloric acid and glacial acetic acid were of analytical grade. 
Ultrapure water was prepared using an EPED super-purification system (Eped, Nanjing, China). 
4.4. Drug Administration and Collection of Rat Plasma Samples 
Experiments  were  performed  on  18  female  and  18  male  Sprague  Dawley  (SD)  rats  randomly 
divided into six groups. Three normal control groups and three blood deficiency model groups were 
administrated  of  RAS,  RLC,  and  herb  pair  RAS-RLC  extract,  respectively.  The  blood  deficiency 
model groups were given hypodermic injection with 2% APH on the 1st day, every other day a time, 
and total of five times at the dosage of 100, 50, 50, 30, 30 mg/kg body mass, respectively [32,42]. Int. J. Mol. Sci. 2012, 13  3592 
 
 
Orbit blood of rat was collected 1.5 h after the last injection to detect red blood cell (RBC), white 
blood cell (WBC), hemoglobin (HGB), and hematocrit (HCT). 
On  the  10th  day,  the  animals  were  given  intragastrically  RAS,  RLC,  and  RAS-RLC  extract 
dissolved  and  dispersed  homogeneously  in  ultrapure  water.  The  animal  dose  of  RAS,  RLC,  and  
RAS-RLC  extract  was  extrapolated  from  the  human  daily  dose,  using  the  body  surface  area 
normalization method [46]. The dose (8.10 g crude herbs per 1 kg rat body weight) of RAS, RLC, and 
RAS-RLC extract was equivalent to five times of the adult daily dose herb pair RAS-RLC (18 g, from 
Si-Wu-Tang in which RAS, RLC, Rehmanniae Radix, and Paeonia Radix were 9 g, respectively) crude 
herbs based on the traditional Chinese medicine prescription, at a dose of 6.48, 7.19, 7.35 mg/kg FA 
(1.5 mL extract per 100 g body weight). The formula for dose translation was as follows: human dose 
of crude herbs in clinic ×  0.018/200 ×  1000 ×  the multiple of clinical equivalency dose. Blood samples 
(0.5 mL) were collected at the designated time points (0, 2, 5, 15, 30, 60, 90, 120, 180, and 240 min) 
after dosing into heparinized Eppendorf centrifuge tubes. Plasma was prepared by centrifuging each 
blood  sample  at  3000×   g  for  10  min  and  the  resulting  plasma  layers  were  stored  in  Eppendorf 
centrifuge  tubes  at  −20  ° C  until  analysis.  Data  from  these  samples  were  used  to  construct  the 
pharmacokinetic profiles by plotting drug concentration vs. time curves. 
4.5. Plasma Sample Preparation 
The thawed plasma samples (100 μL) were transferred to a 1.5 mL Eppendorf centrifuge tube, 
added with 20 μL IS (0.37 mg/mL) and then mixed with 50 μL 0.1 mol/L hydrochloric acid and  
850 μL ethyl acetate. Afterwards mixture was vortexed for 1 min and centrifuged at 3000×  g for 5 min 
at ambient temperature. Supernatant (800 μL) was transferred into a 1.5 mL Eppendorf centrifuge tube 
and evaporated to dryness under the stream of nitrogen at 40 ° C, the residue was dissolved in 100 μL 
of mobile phase, and the mixture was vortexed for 1 min and centrifuged at 13,000×  g for 5 min at 
ambient temperature. Finally, a 10 μL aliquot of supernatant was injected into HPLC for analysis. 
4.6. Chromatographic Conditions 
Analysis was performed on a Waters 2695 Alliance HPLC system (Waters Corp., USA) equipped 
with a 2996 photodiode array detector (PDA) together with a quaternary pump solvent management 
system, an on-line degasser and an autosampler. The analytes were separated on a Hedera™ ODS-2 
column (250 mm ￗ 4.6 mm, 5 μm) from Jiangsu Hanbon Sci and Tech Co. Ltd. (Jiangsu, China). The 
mobile phase was composed of solvent A (0.3% aqueous glacial acetic acid, v/v) and B (acetonitrile), 
the gradient program was set as follows: 20–40% B at 0–5 min, 40–60% B at 5–12 min. The flow  
rate was 1.0 mL/min and detection wavelength was set at 320 nm. The operating temperature was 
maintained at 35 ° C. 
4.6.1. Linearity 
Primary stock solutions of FA and IS were prepared by dissolving accurately weighed FA and IS in 
methanol to yield a final concentration of 0.219 and 0.37 mg/mL, respectively. For the calibration 
curve,  six  concentrations  (0.1095,  0.5475,  1.095,  2.19,  4.38,  10.95  μg/mL)  of  FA  solution  were Int. J. Mol. Sci. 2012, 13  3593 
 
 
prepared by dilution of the stock solution. The serial solutions (10 μL) were spiked in 100 μL blank 
plasma, then 20 μL of the IS solution were added. Afterwards, calibration standards were processed 
and assayed as described above, and 10 L aliquot of supernatant was injected into HPLC for analysis. 
The calibration curves in the range of 0.1095~10.95 μg/mL for FA were constructed by plotting the 
ratio of peak area between FA and IS against the FA standard concentrations using least-square method. 
4.6.2. Recovery and Accuracy 
Three concentrations (high, medium, and low) of standard solution mixture in the blank rat plasma 
were detected five times on the same day for intra-day and continuously for five days for the inter-day 
accuracy variation test. The precision coefficient of variation (RSD) was calculated from the observed 
concentration  (Cobs)  as  following  equation:  %RSD  =  [standard  deviation  (S.D.)/Cobs]  ×   100.  The 
recovery rates (%) were calculated from the mean value of the observed concentration (Cobs) and the 
theoretical concentrations (Cthe) as following equation: % = [Cobs/Cthe] ×  100. 
4.7. Pharmacokinetic Analysis 
The pharmacokinetic data analysis was processed by a pharmacokinetic software package of DAS 
2.1 which is edited by the Mathematics Pharmacological Committee, Chinese Pharmacological Society. 
The  values  of  the  experimental  data  and  the  pharmacokinetic  parameters  were  expressed  as  
mean  S.D. The following pharmacokinetic parameters such as elimination half-life (t1/2, t1/2), area 
under  the  plasma  concentration-time  curve  from  zero  to  the  last  experimental  point  240  min  
(AUC0–240),  the  area  under  the  plasma  concentration-time  curve  from  zero  to  infinity  (AUC0–limit), 
clearance  (CL),  volume  of  distribution  (Vd),  rate  constants  of  transport  between  the  central  and 
peripheral compartments (K12 and K21), the elimination rate constant (K10), the maximum concentration 
(Cmax),  and  time  of  maximum  plasma  concentration  (tmax)  were  calculated  by  the  compartmental 
pharmacokinetic analysis. A statistical analysis was performed using an analysis of variance (ANOVA). 
A P value < 0.05 was considered statistically significant and P < 0.01 being very significant. 
5. Conclusion 
This study suggested that the pharmacokinetic process of herbs will alter in pathological conditions, 
and can be influenced by other herbs when they are used as a herb pair or formulae. The knowledge of 
the pharmacokinetic processes of herb pair or formulae in normal and pathological conditions can help 
us explain and predict a variety of events related to the efficacy and toxicity of TCM. 
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